Skip to content

An observational clinical study to evaluate the immune response characteristics of COVID-19 vaccine in Chinese cancer population

An observational clinical study to evaluate the immune response characteristics of COVID-19 vaccine in Chinese cancer population

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046840
Enrollment
Unknown
Registered
2021-05-29
Start date
2021-06-01
Completion date
Unknown
Last updated
2024-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer/tumor

Interventions

Sponsors

The Sixth Peoples Hospital of Shenyang
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Plan to shoot COVID-19 vaccine; 2. The patients diagnosed with tumor; 3. Participants who are willing and able to comply with all scheduled follow-up, vaccination plans, laboratory tests and other research procedures; 4. Voluntary vaccination without contraindication; 5. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Aged =70 years; 2. Pregnant and lactating women; 3. Other conditions considered unsuitable for inclusion in the study; 4. At present, patients complicated with tumor metastasis, liver failure, renal failure, respiratory failure and heart failure; 5. Patients who were diagnosed as tumor but were in the perioperative period or undergoing radiotherapy or chemotherapy; 6. Patients with acute infection, fever and so on; 7. Patients with other immune related diseases, such as AIDS, immunodeficiency, autoimmune diseases and so on.

Design outcomes

Primary

MeasureTime frame
neutralizing antibody;

Secondary

MeasureTime frame
T cell subsets;

Countries

China

Contacts

Public ContactGu Ye

The Sixth Peoples Hospital of Shenyang

sylykjk@163.com+86 24-23260027

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026